Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DM376WT)

Drug Name
NKTR 214 Drug Info
Indication
Disease Entry ICD 11 Status REF
Melanoma 2C30 Phase 3 [1]
Sarcoma 2A60-2C35 Phase 2 [2]
Bladder cancer 2C94 Phase 1/2 [3]
Colorectal cancer 2B91.Z Phase 1/2 [3]
Renal cell carcinoma 2C90 Phase 1/2 [3]
Solid tumour/cancer 2A00-2F9Z Phase 1/2 [2]
Cross-matching ID
TTD Drug ID
DM376WT

Molecule(s) Related to This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Interleukin 2 receptor beta (IL2RB) TT9721Y IL2RB_HUMAN Agonist [3]

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule Molecule Type Gene Name Liver Colon Kidney Small Intestine
Interleukin 2 receptor beta (IL2RB) DTT IL2RB 7.492 7.017 6.785 7.933
Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease Melanoma
ICD Disease Classification 2C30
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Interleukin 2 receptor beta (IL2RB) DTT IL2RB 7.52E-01 -0.06 -1.11
Interleukin 2 receptor beta (IL2RB) DTT IL2RB 1.96E-01 -4.70E-03 -0.01
Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1 ClinicalTrials.gov (NCT03635983) A Study of NKTR-214 Combined With Nivolumab vs Nivolumab Alone in Participants With Previously Untreated Inoperable or Metastatic Melanoma. U.S. National Institutes of Health.
2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)